Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Crinetics Pharmaceuticals Inc.
M.D. Anderson Cancer Center
ViroMissile, Inc.
Exelixis
Cedars-Sinai Medical Center
Boston Scientific Corporation
SystImmune Inc.
Hoffmann-La Roche
Changi General Hospital
UNICANCER
AccSalus Biosciences, Inc.
Cook Group Incorporated
MedSIR
Hutchmed
National Cancer Institute (NCI)
University of Sao Paulo
Federation Francophone de Cancerologie Digestive
Dana-Farber Cancer Institute
Peking Union Medical College Hospital
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Peking Union Medical College Hospital
H. Lee Moffitt Cancer Center and Research Institute
Institut Bergonié
Novartis
Provectus Pharmaceuticals
Boston Scientific Corporation
Amgen
SpeciCare
Xiangya Hospital of Central South University
Case Comprehensive Cancer Center
Fudan University
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hospices Civils de Lyon
Eli Lilly and Company
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Yale University
Yale University
Massachusetts General Hospital
Novartis
GERCOR - Multidisciplinary Oncology Cooperative Group
INSYS Therapeutics Inc
Peking University
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
European Organisation for Research and Treatment of Cancer - EORTC